AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25944802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan at 8 and 10 mg/kg
Number of subjects: 25
Study 25944802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 25
Study 25944944 — intervention group
Group type: EXPERIMENTAL
Intervention: SootherMask (InspiRx) small mask
Number of subjects: 270
Study 25944944 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex (Pari) small mask
Number of subjects: 270
Study 25944944 — intervention group
Group type: EXPERIMENTAL
Intervention: SootherMask (InspiRx) medium mask
Number of subjects: 270
Study 25944944 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroChamber (Monaghan Medical) medium mask
Number of subjects: 270
Study 25944944 — intervention group
Group type: COMPARATOR
Intervention: Various face masks (small and medium)
Number of subjects: 270
Study 25944944 — intervention group
Group type: EXPERIMENTAL
Intervention: InspiRx masks (small and medium)
Number of subjects: 270
Study 25945597 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Paced Visual Serial Attention Task (APVSAT) used at least three times per week for four weeks
Number of subjects: 27
Study 25945924 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDR 3D mild
Number of subjects: 30
Study 25945924 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDR 3D standard
Number of subjects: 30
Study 25945924 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDR 3D strong
Number of subjects: 30
Study 25945924 — intervention group
Group type: COMPARATOR
Intervention: FBP/QDS
Number of subjects: 30
Study 25946437 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN XT transcatheter heart valve
Number of subjects: 2688
Study 25947565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib (escalating doses on day 1) + Epirubicin (standard dose on day 2)
Number of subjects: 9
Study 25947955 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25948541 — intervention group
Group type: EXPERIMENTAL
Intervention: Approved clinical decision values (CDVs) for hs-cTn assays (hs-cTnI, Abbott; hs-cTnT, Roche)
Number of subjects: 2300
Study 25948541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-specific CDVs
Number of subjects: 2300
Study 25948541 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically equivalent CDV
Number of subjects: 2300
Study 25948541 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn assays with nearly biologically equivalent CDVs
Number of subjects: 2300
Study 25948541 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with inconsistent AMI diagnoses
Number of subjects: 2300
Study 25948542 — intervention group
Group type: EXPERIMENTAL
Intervention: More sensitive cardiac troponin (cTn) assays (3 sensitive and 4 high-sensitivity cTn assays)
Number of subjects: 447
Study 25948542 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal receiver-operator characteristic curve-derived cTn cutoff levels
Number of subjects: 447
Study 25948664 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher usual alcohol consumption (10-g increment)
Number of subjects: 843
Study 25948664 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher usual alcohol consumption (10-g increment) compared to co-twin
Number of subjects: 843
Study 25948664 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverage types (beer, wine, spirits)
Number of subjects: 843
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinoic acid (RA) concentration in patients with NAFLD (1.42 ± 0.47 ng/mL)
Number of subjects: 124
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinoic acid (RA) concentration in patients with NASH (1.14 ± 0.26 ng/mL)
Number of subjects: 124
Study 25948673 — intervention group
Group type: COMPARATOR
Intervention: Serum RA concentrations in control subjects with normal glucose tolerance (2.87 ± 0.52 ng/mL)
Number of subjects: 124
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RA concentrations in NAFLD patients with normal glucose tolerance (1.61 ± 0.37 ng/mL)
Number of subjects: 124
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RA concentrations in NASH patients with normal glucose tolerance (1.35 ± 0.34 ng/mL)
Number of subjects: 124
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: RXRα mRNA expression in liver tissue
Number of subjects: 124
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RA concentrations
Number of subjects: 124
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: RXRα mRNA levels
Number of subjects: 124
Study 25948673 — intervention group
Group type: EXPERIMENTAL
Intervention: RXRα protein concentration in patients with NAFLD
Number of subjects: 124
Study 25948783 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Score (HLS)
Number of subjects: 787
Study 25948783 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and network component of HLS
Number of subjects: 787
Study 25948783 — intervention group
Group type: COMPARATOR
Intervention: Individual lifestyle components
Number of subjects: 787
Study 25948786 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal macronutrient intake (energy, protein, fat, carbohydrates)
Number of subjects: 835
Study 25948786 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate intake
Number of subjects: 835
Study 25948786 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fat intake
Number of subjects: 835
Study 25948786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower protein intake
Number of subjects: 835
Study 25950507 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Adaptive Servoventilation (ASV)
Number of subjects: 27
Study 25950507 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 27
Study 25950694 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 251
Study 25950694 — intervention group
Group type: COMPARATOR
Intervention: Reference (unchanged lifestyle)
Number of subjects: 251
Study 25951716 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (30 mg, 3 times a day, orally for 3 months)
Number of subjects: 10
Study 25952086 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-directed transgastric ERCP (EDGE) using a lumen-apposing metal stent (LAMS)
Number of subjects: 5
Study 25952091 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent CBDS group (n=32)
Number of subjects: 64
Study 25952091 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 64
Study 25952707 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported STI history among sexually active youth
Number of subjects: 4389
Study 25952707 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and behavioral correlates of STI history
Number of subjects: 4389
Study 25952707 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of STI history between genders
Number of subjects: 4389
Study 25952795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004 (12 mg/kg weekly infusions)
Number of subjects: 26
Study 25952796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich-like neoadjuvant therapy with bevacizumab (induction therapy with bevacizumab and FOLFOX, concurrent chemoradiotherapy with bevacizumab and consolidation chemotherapy with FOLFOX)
Number of subjects: 25
Study 25952796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich-like neoadjuvant therapy with bevacizumab
Number of subjects: 25
Study 25953016 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUSEAL graft (early-cannulation AVG)
Number of subjects: 138
Study 25953374 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary Index Score (CIS) favorable (fCIS=2 or 3) with good revascularization (modified thrombolysis in cerebral infarction score 2b or 3)
Number of subjects: 78
Study 25953374 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary Index Score (CIS) poor (pCIS=0 or 1) with good revascularization (modified thrombolysis in cerebral infarction score 2b or 3)
Number of subjects: 78
Study 25953601 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal distraction during bottle-feeding
Number of subjects: 28
Study 25953601 — intervention group
Group type: COMPARATOR
Intervention: Not distracted mothers
Number of subjects: 28
Study 25953829 — intervention group
Group type: EXPERIMENTAL
Intervention: MODY3
Number of subjects: 30
Study 25953829 — intervention group
Group type: COMPARATOR
Intervention: CTRLs
Number of subjects: 30
Study 25953829 — intervention group
Group type: EXPERIMENTAL
Intervention: MODY2
Number of subjects: 30
Study 25954318 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca root (3.0 g/day)
Number of subjects: 45
Study 25954318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25954817 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational intervention led by Community Health Representatives (CHRs) including a one hour group didactic session and monthly home-based educational interventions for 6 months.
Number of subjects: 60
Study 25954817 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational intervention led by Community Health Representatives (CHRs) for 6 months.
Number of subjects: 60
Study 25955252 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer navigation TKA
Number of subjects: 87
Study 25955252 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 87
Study 25955319 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 25955359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless amniotic membrane transplantation using AmnioClip
Number of subjects: 7
Study 25955359 — intervention group
Group type: EXPERIMENTAL
Intervention: AmnioClip application
Number of subjects: 7
Study 25955404 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 11
Study 25955404 — intervention group
Group type: COMPARATOR
Intervention: Partial Sleep Deprivation (PSD)
Number of subjects: 11
Study 25955404 — intervention group
Group type: COMPARATOR
Intervention: Well-rested state
Number of subjects: 11
Study 25955492 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic and targeted agents
Number of subjects: 23
Study 25956314 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 25956314 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25956795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally once per day and depot octreotide at preprotocol dosage
Number of subjects: 52
Study 25956918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30, 60 or 90 mg) in combination with another antihypertensive agent
Number of subjects: 4497
Study 25957377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Number of subjects: 31
Study 25957391 — intervention group
Group type: EXPERIMENTAL
Intervention: modified CODOX-M/IVAC-rituximab regimen
Number of subjects: 34
Study 25957497 — intervention group
Group type: EXPERIMENTAL
Intervention: α-1-Acid glycoprotein (AGP)
Number of subjects: 277
Study 25957497 — intervention group
Group type: EXPERIMENTAL
Intervention: AGP, SOFA scores, and SOFA + AGP
Number of subjects: 277
Study 25957497 — intervention group
Group type: EXPERIMENTAL
Intervention: AGP, SOFA, Acute Physiology and Chronic Health Evaluation II, length of ICU stay
Number of subjects: 277
Study 25957999 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3965 (inhibitor of MCT1)
Number of subjects: 0
Study 25957999 — intervention group
Group type: COMPARATOR
Intervention: Control cell lines (K562 for MCT1 and MDAMB231 for MCT4)
Number of subjects: 0
Study 25958200 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Number of subjects: 0
Study 25958200 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 25958200 — intervention group
Group type: EXPERIMENTAL
Intervention: Venue-based sampling
Number of subjects: 0
Study 25958200 — intervention group
Group type: COMPARATOR
Intervention: Respondent-driven sampling (RDS)
Number of subjects: 0
Study 25958314 — intervention group
Group type: EXPERIMENTAL
Intervention: H3-L6 intervention (increased omega-3 fatty acids, reduced omega-6 linoleic acid)
Number of subjects: 55
Study 25959555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 22
Study 25959555 — intervention group
Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 22
Study 25960972 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course IV antibiotic treatment (ceftriaxone and metronidazole) for up to 5 days followed by 5 days of oral antibiotics
Number of subjects: 256
Study 25960972 — intervention group
Group type: COMPARATOR
Intervention: Long-course IV antibiotic treatment (between days 5 and 10)
Number of subjects: 256
Study 25961446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM system (software 505) with hypoglycemic alert set at 80 mg/dL
Number of subjects: 0
Study 25961446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM system (software 505)
Number of subjects: 0
Study 25961903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce distress in mothers of preterm infants
Number of subjects: 105
Study 25961903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional coping style, high depression, anxiety, or trauma symptoms, and low social support
Number of subjects: 105
Study 25961903 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal response to trauma
Number of subjects: 105
Study 25961903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional coping style
Number of subjects: 105
Study 25962426 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg weekly in a 3-week cycle (MTD determined in Phase I)
Number of subjects: 55
Study 25962439 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp-SP (sulphadoxine-pyrimethamine)
Number of subjects: 245
Study 25962554 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) via nasojejunal (NJ) tube and then switched to percutaneous endoscopic gastrojejunostomy (PEG-J) tube in open-label study
Number of subjects: 391
Study 25962554 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) replacing daytime oral levodopa-carbidopa in double-blind trial
Number of subjects: 391
Study 25962554 — intervention group
Group type: COMPARATOR
Intervention: Nasojejunal (NJ) treatment in open-label study
Number of subjects: 391
Study 25962554 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-J weeks 1-4 in open-label/monotherapy trial
Number of subjects: 391
Study 25962554 — intervention group
Group type: COMPARATOR
Intervention: PEG-J weeks 1-4 in double-blind/polypharmacy trial
Number of subjects: 391
Study 25962717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004 (9 and 12 mg/kg weekly)
Number of subjects: 39
Study 25962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 4 weeks
Number of subjects: 62
Study 25962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for men with elevated baseline hs-CRP (≥2 mg/l)
Number of subjects: 62
Study 25962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for men with lower baseline hs-CRP
Number of subjects: 62
Study 25962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for women
Number of subjects: 62
Study 25963019 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 33
Study 25963185 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 105
Study 25963185 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with myofascial pelvic pain
Number of subjects: 105
Study 25963185 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with interstitial cystitis/bladder pain syndrome
Number of subjects: 105
Study 25963185 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with interstitial cystitis/bladder pain syndrome plus myofascial pelvic pain
Number of subjects: 105
Study 25963190 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 728
Study 25963190 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage lymph node dissection
Number of subjects: 728
Study 25963190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and salvage lymph node dissection
Number of subjects: 728
Study 25963190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy
Number of subjects: 728
Study 25963190 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hormone therapy as the only salvage treatment
Number of subjects: 728
Study 25963190 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings from clinical series
Number of subjects: 728
Study 25963299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fanconi anemia (FA)
Number of subjects: 118
Study 25963299 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyskeratosis congenita (DC)
Number of subjects: 118
Study 25963299 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond-Blackfan anemia (DBA) and Shwachman-Diamond syndrome (SDS)
Number of subjects: 118
Study 25963299 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe bone marrow failure (BMF)
Number of subjects: 118
Study 25963299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall immune function
Number of subjects: 118
Study 25963722 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 50 mg
Number of subjects: 13
Study 25963722 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 100 mg
Number of subjects: 13
Study 25963722 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 15 mg
Number of subjects: 13
Study 25963722 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 (all doses)
Number of subjects: 13
Study 25963988 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg intravenous once daily
Number of subjects: 20
Study 25964244 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1775, 225 mg orally twice per day over 2.5 days per week for 2 weeks per 21-day cycle
Number of subjects: 25
Study 25964244 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1775
Number of subjects: 25
Study 25964250 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant regimen of gemcitabine (1,000 mg/m(2) intravenously on days 1 and 8) and capecitabine (1,500 mg/m(2) per day on days 1 to 14) followed by concurrent capecitabine (1,330 mg/m(2) per day) and radiotherapy (45 Gy to regional lymphatics; 54 to 59.4 Gy to tumor bed)
Number of subjects: 79
Study 25964296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (10 μg/mL)
Number of subjects: 0
Study 25964296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (10 mg/kg/dose)
Number of subjects: 0
Study 25964296 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (10 mg/kg/dose)
Number of subjects: 0
Study 25964395 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (50% reduction) for 6 weeks
Number of subjects: 0
Study 25964505 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (8-week open-label trial)
Number of subjects: 83
Study 25964591 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Debulking Surgery (PDS)
Number of subjects: 573
Study 25964591 — intervention group
Group type: COMPARATOR
Intervention: Interval Debulking Surgery (I-IDS)
Number of subjects: 573
Study 25964591 — intervention group
Group type: COMPARATOR
Intervention: Referred-Interval Debulking Surgery (R-IDS)
Number of subjects: 573
Study 25964599 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 58
Study 25964643 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary radiation therapy in combined modality therapy
Number of subjects: 0
Study 25964643 — intervention group
Group type: COMPARATOR
Intervention: Omission of radiation
Number of subjects: 0
Study 25965712 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 10132
Study 25965712 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for OSA
Number of subjects: 10132
Study 25966740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg) injection every 28 days for three consecutive months followed by a fourth injection 8 weeks later.
Number of subjects: 16
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-lifestyle physical activity
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-vigorous physical activity (MVPA)
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shuttle Test (MST) performance
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life - Social Functioning (QOL-B)
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life - Respiratory Symptoms (QOL-B)
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance 'pros' score
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in one-second percentage predicted (FEV1% predicted)
Number of subjects: 63
Study 25967368 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 63
Study 25967578 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1
Study 25967993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT)
Number of subjects: 114
Study 25967993 — intervention group
Group type: COMPARATOR
Intervention: Baseline blood values
Number of subjects: 114
Study 25968087 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25968306 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels
Number of subjects: 211
Study 25968306 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone level
Number of subjects: 211